Cellosaurus IGROV-1 (CVCL_1304)

Cell line name IGROV-1
Synonyms Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P
Accession CVCL_1304
Resource Identification Initiative To cite this cell line use: IGROV-1 (RRID:CVCL_1304)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI60 cancer cell line panel.
Part of: OCCP ovarian cancer cell line panel.
Doubling time: 30 hours (PubMed=25984343); ~23 hours (PubMed=10817511); 31 hours (NCI-DTP).
Microsatellite instability: Instable (MSI-high) (Sanger).
Sequence variation: Heterozygous for BRCA1 p.Lys654fs*47 (PubMed=17088437).
Sequence variation: Heterozygous for SMAD4 p.Gly231fs*10 (PubMed=17088437).
Sequence variation: Heterozygous for PTEN p.Thr319fs*1 (PubMed=17088437).
Sequence variation: Heterozygous for TP53 p.Tyr126Cys (PubMed=17088437).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: IGROV-4; In PubMed=12960427.
Misspelling: IGR-OV1-RU; In Cosmic 1175880.
Disease Ovarian endometrioid adenocarcinoma (NCIt: C7979)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_8723 (IGROV-1/25 ET); CVCL_4Y61 (IGROV-1/APL); CVCL_IQ21 (IGROV-1/CP); CVCL_EQ59 (IGROV-1/MX3); CVCL_EQ61 (IGROV-1/Pt0.5); CVCL_EQ62 (IGROV-1/Pt1); CVCL_EQ60 (IGROV-1/T8); CVCL_4V48 (IGROV(T100r)); CVCL_8744 (OV1/ADR); CVCL_8745 (OV1/CDDP); CVCL_8746 (OV1/VCR)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; PubMed=19372543; PubMed=25230021; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,13,14,15 (Cosmic-CLP)
11,13 (PubMed=19372543)
11,16 (PubMed=25230021)
11,13,15 (PubMed=25877200)
D13S3178,10
D16S53911,12 (Cosmic-CLP; PubMed=19372543; PubMed=25877200)
12 (PubMed=25230021)
D18S5114,16,17 (PubMed=25230021)
15,16 (PubMed=25877200)
D19S43313,14
D21S1126,29.2,30.2 (PubMed=25230021)
26,30.2 (PubMed=25877200)
D2S133817,25
D3S135813,15 (PubMed=19372543)
13,14,15 (PubMed=25230021; PubMed=25877200)
D5S81812,13 (Cosmic-CLP; PubMed=19372543; PubMed=25230021)
12 (PubMed=25877200)
D7S82011 (Cosmic-CLP)
10 (PubMed=25877200)
9.1,10.1,11.1 (PubMed=25230021)
D8S117914,16
FGA20,21,26 (PubMed=25230021)
21,26 (PubMed=25877200)
Penta D8,10
Penta E13,17
TH017,9.3
TPOX8,11,12 (Cosmic-CLP)
8,11 (PubMed=19372543; PubMed=25230021; PubMed=25877200)
vWA17,21 (Cosmic-CLP; PubMed=19372543)
16,17,20,22 (PubMed=25230021)
17,21,22 (PubMed=25877200)
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=26
Publications

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10817511; DOI=10.1054/bjoc.2000.1224
Erba E., Bergamaschi D., Bassano L., Ronzoni S., Di Liberti G., Muradore I., Vignati S., Faircloth G.T., Jimeno J., D'Incalci M.
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Br. J. Cancer 82:1732-1739(2000)

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279
Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.
Gene expression patterns in ovarian carcinomas.
Mol. Biol. Cell 14:4376-4386(2003)

PubMed=16319398; DOI=10.1074/mcp.M500140-MCP200
Stewart J.J., White J.T., Yan X., Collins S., Drescher C.W., Urban N.D., Hood L.E., Lin B.-Y.
Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.
Mol. Cell. Proteomics 5:433-443(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23913215; DOI=10.1007/978-1-62703-547-7_12
Li L.-S., Liu J., Yu W., Lou X.-Y., Huang B.-D., Lin B.-Y.
Deep transcriptome profiling of ovarian cancer cells using next-generation sequencing approach.
Methods Mol. Biol. 1049:139-169(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028
Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Gynecol. Oncol. 142:332-340(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645-12645(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections NCI-DTP; IGR-OV1
Cell line databases/resources CLDB; cl2627
CCLE; IGROV1_OVARY
Cosmic-CLP; 905968
GDSC; 905968
Lonza; 175
SKY/M-FISH/CGH; 2739
Ontologies BTO; BTO:0002575
CLO; CLO_0006672
EFO; EFO_0005385
Biological sample resources BioSample; SAMN03470926
Chemistry resources ChEMBL-Cells; CHEMBL3307502
ChEMBL-Targets; CHEMBL613984
Gene expression databases GEO; GSM2127
GEO; GSE23440
GEO; GSE25191
GEO; GSM50218
GEO; GSM50281
GEO; GSM313715
GEO; GSM750827
GEO; GSM799361
GEO; GSM799424
GEO; GSM844567
GEO; GSM844568
GEO; GSM844569
GEO; GSM844570
GEO; GSM846360
GEO; GSM851919
GEO; GSM887160
GEO; GSM888232
GEO; GSM1153432
GEO; GSM1181284
GEO; GSM1181285
GEO; GSM1291142
GEO; GSM1374571
GEO; GSM1669930
GEO; GSM2124667
Polymorphism and mutation databases Cosmic; 688100
Cosmic; 875857
Cosmic; 897430
Cosmic; 905968
Cosmic; 920360
Cosmic; 947357
Cosmic; 1044236
Cosmic; 1092607
Cosmic; 1102823
Cosmic; 1175880
Cosmic; 1305334
Cosmic; 1312353
Cosmic; 1707557
Cosmic; 1709252
Cosmic; 1998449
Cosmic; 2464669